IPO
-
-
-
-
-
-
-
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
-
-
-
-
-
-
122,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

